Know Cancer

or
forgot password

A Phase I/II Clinical Trial of Combination of Irinotecan, Xeloda and Oxaliplatin (IXO) Regimen With Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer


Phase 1/Phase 2
18 Years
N/A
Open (Enrolling)
Both
Metastatic Colorectal Cancer

Thank you

Trial Information

A Phase I/II Clinical Trial of Combination of Irinotecan, Xeloda and Oxaliplatin (IXO) Regimen With Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer


Inclusion Criteria:



- Histologically documented adenocarcinoma of the colon or rectum.

- Advanced and/or metastatic disease, incurable with standard therapy.

- Unresectable advanced and/or metastatic unidimensionally measurable disease (RECIST
scale).

- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

- Age: over 18 years.

- Adequate haematological, renal and hepatic functions

- Patient consent must be obtained according to local REB requirements.

- Patients must be accessible for treatment and follow up.

Exclusion Criteria:

- Previous or concurrent malignancies

- Pregnant or lactating women. Women of childbearing potential must have had a negative
pregnancy test within 7 days prior to registration.

- Concurrent treatment with other experimental drugs or anticancer therapy.

- Previous chemotherapy for advanced and/or metastatic disease.

- Previous adjuvant therapy with irinotecan or oxaliplatin.

- Previous full dose curative pelvic radiation therapy.

- Patients with documented brain metastases.

- Serious illness or medical condition.

- Gilbert's disease

- Use of enzyme inducing anticonvulsants such as phenytoin, phenobarbital and
carbamazepine

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Phase I: Assess the MTD and RD for phase II of IXO and bevacizumab combination given every 3 weeks in 1st line patients with mCRC

Outcome Time Frame:

3-week cycle, continuous monitoring of AE

Safety Issue:

Yes

Principal Investigator

Jean Maroun, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

The Ottawa Hospital Cancer Centre

Authority:

Canada: Health Canada

Study ID:

0TT 03-03

NCT ID:

NCT00819754

Start Date:

November 2003

Completion Date:

July 2013

Related Keywords:

  • Metastatic Colorectal Cancer
  • Colorectal Neoplasms

Name

Location